Immmunotherapy-based treatments demonstrate effectiveness and safety profiles consistent with clinical trials in real-world setting.

Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in ...

Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study.. If you have the ...

In August 2025, Bristol-Myers Squibb announced a study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in ...

Already USFDA-approved, under-the-skin jab can be administered in just seven minutes to the patient. This is dramatic cut ...

In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed ...

To our knowledge, the SOGUG-AUREA trial showed, for the first time, that the combination of atezolizumab with split doses of cisplatin and gemcitabine was effective and safe for patients with mUC ,” ...

Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.

Recent clinical trials like ADRIATIC and IMforte are shaping the future of small cell lung cancer (SCLC) treatment, explained Angel Qin, MD. She also emphasized the growing role of immunotherapy in ...